Mablink Bioscience to be acquired by Lilly

Mablink Bioscience, a pre-clinical biotechnology company pioneering the development of next-generation antibody-drug conjugates (ADCs) via its PSARLink™ proprietary platform, has announced an agreement to be acquired by Eli Lilly and Company (Lilly).

PSARlink™, an innovative hydrophilic linker using a polysarcosine arm, holds potential for broadening the therapeutic index of ADCs to unleash their full therapeutic impact.

Jean-Guillaume Lafay, Mablink’s Chief Executive Officer, stated: “Mablink’s agreement to be acquired by Lilly is a strong endorsement of our approach, our technology and our team.

“The values we share with Lilly, and our combined expertise are also a unique opportunity to leverage Mablink’s capabilities and endeavors to potentially bring transformative therapies to cancer patients with high unmet medical needs. Our thanks go to all inside and outside Mablink who have supported our efforts and development since inception.”

The transaction is subject to approval from the French Ministry of the Economy.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news